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ABSTRACT
Introduction: Effective management of type 2
diabetes requires sustained glycemic control
over many years, which can be particularly
challenging for elderly people. This sub-analysis
of the A1chieve study evaluated the clinical
safety and effectiveness of biphasic insulin
aspart 30 in 3 age-groups (B40, [40–65, and
[65 years) of previously insulin-experienced
and insulin-naı¨ve people with type 2 diabetes.
Methods: A1chieve was an international,
multicenter, prospective, open-label, non-
interventional, 24-week study in people with
type 2 diabetes who had been receiving anti-
diabetes medication before starting, or
switching to, therapy with biphasic insulin
aspart 30, insulin detemir or insulin aspart
(alone or in combination) in routine clinical
practice. This sub-analysis evaluated clinical
safety and effectiveness of biphasic insulin
aspart 30 (±oral glucose-lowering drugs) in
different age-groups.
Results: Data on 40,122 participants were
included. In all age-groups, the proportion ofThis trial was registered with ClinicalTrials.gov
(NCT00869908).
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participants experiencing any hypoglycemia,
major hypoglycemia or nocturnal hypoglycemia
was significantly reduced from baseline, except for
the following in insulin-naı¨ve patients: a
significant increase in any hypoglycemia in
patients aged [65 years; no change in any
hypoglycemia, major hypoglycemia, and
nocturnal hypoglycemia in patients aged
[40–65, B40, and [65 years, respectively.
Significant improvements at 24 weeks vs.
baseline were observed in insulin-experienced
and insulin-naı¨ve participants for: glycated
hemoglobin (change from baseline ranged from
-1.8% to -2.4%); fasting plasma glucose (from -
3.0 to -4.3 mmol/l); post-breakfast post-prandial
plasma glucose (from -4.1 to -6.5 mmol/l); and
health-related quality of life (HRQoL). Sixteen
serious adverse drug reactions were reported.
Conclusion: After 24-week treatment with
biphasic insulin aspart 30, all age-groups of
insulin-experienced and insulin-naı¨ve patients
experienced significantly improved glycemic
control and HRQoL; incidence of
hypoglycemia was generally reduced. The
tolerability and effectiveness of biphasic
insulin aspart 30 may benefit all age-groups.
Keywords: Biphasic insulin aspart; Non-
interventional study; Observational study;
Type 2 diabetes
INTRODUCTION
Worldwide, an estimated 366 million people
had diabetes in 2011 and the number is
expected to grow to 552 million by 2030 [1].
The 2005–2006 National Health and Nutrition
Examination Survey of community-dwelling
adults showed that the prevalence of diabetes
increases with age, peaking at 60–74 years of age
(crude prevalence 17.6%) [2].
Effective management of diabetes requires
sustained glycemic control over many years.
This can be a challenge for all patients with
diabetes, but particularly in elderly people with
type 2 diabetes, due to co-morbidities and
polypharmacy, among other issues.
Furthermore, elderly patients may find it
difficult to adequately self-monitor blood
sugar levels due to poor dexterity, and
cognitive and visual impairments, and may
have impaired awareness of hypoglycemia
compared with younger patients [3, 4].
Consequently, elderly people with type 2
diabetes have a higher rate of severe
hypoglycemia than younger people with type
2 diabetes [5, 6].
Insulin analogs were developed to help
people with diabetes improve their glycemic
control and to address concerns over insulin
therapy, particularly hypoglycemia and weight
gain [7, 8]. Randomized controlled trials (RCTs)
and non-interventional studies [9–16] have
shown that a change of therapy from oral
glucose-lowering drugs (OGLDs) or
conventional insulin preparations to insulin
analogs can be associated with clinically
significant improvements in effectiveness
measures and tolerability.
For many patients, biphasic insulin
formulations offer a simple-to-use insulin
regimen [17], providing greater lifestyle
flexibility for the patient; they also offer the
advantage of controlling both fasting plasma
glucose (FPG) and post-prandial glucose (PPG)
[18, 19]. Biphasic insulin aspart 30 (NovoMix
30; Novo Nordisk A/S, Bagsvaerd, Denmark) may
lead to improved PPG control compared with
other insulin therapies, including premixed
biosynthetic human insulin 30, and biphasic
insulin lispro [20]. Furthermore, initiating
insulin therapy with once- or twice-daily
biphasic insulin aspart 30 (in people with type 2
348 Diabetes Ther (2013) 4:347–361
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diabetes on various OGLD regimens) effectively
controls glycated hemoglobin (HbA1c) levels [18,
19]. Indeed, one study showed that significantly
more insulin-naı¨ve people with type 2 diabetes
randomized to twice-daily biphasic insulin
aspart 30 achieved HbA1c \7.0% than those
randomized to once-daily insulin glargine,
especially among people with baseline HbA1c
[8.5% [19]. Non-inferiority of once-daily
biphasic insulin aspart 30 to once-daily insulin
glargine has also been shown in people with type
2 diabetes inadequately controlled with OGLDs
[21]. The effectiveness of biphasic insulin aspart
30 seen in short-term studies is maintained with
long-term use [22, 23].
A1chieve was an international non-
interventional study evaluating the safety and
clinical effectiveness of insulin analogs in
people with type 2 diabetes receiving routine
clinical care in 28 countries across 4 continents.
Given that different age-groups can respond
differently to drug therapies, and have differing
needs, this sub-analysis assessed the outcomes
with biphasic insulin aspart 30 (±OGLDs) in 3
age-groups (B40, [40–65 and [65 years) in the
A1chieve study, with and without previous
experience of using insulin.
MATERIALS AND METHODS
A1chieve was an international prospective,
multicenter, open-label, non-interventional,
24-week study in people with type 2 diabetes
mellitus who had been using anti-diabetes
medication before starting, or switching to,
insulin therapy with biphasic insulin aspart 30,
insulin aspart (NovoRapid; Novo Nordisk A/S,
Bagsvaerd, Denmark) or insulin detemir
(Levemir; Novo Nordisk A/S, Bagsvaerd,
Denmark) with or without OGLDs in routine
clinical practice [24]. The study was conducted in
28 countries, representing 7 geographical regions:
China; South Asia (Bangladesh, India, Pakistan);
East Asia (Indonesia, Korea, Malaysia, Philippines,
Singapore, Taiwan); North Africa (Algeria,
Morocco, Tunisia, Libya); Middle East/Gulf
(Egypt, Iran, Jordan, Turkey, Bahrain, Kuwait,
Oman, Qatar, Saudi Arabia, United Arab Emirates,
Yemen); Latin America (Argentina, Mexico); and
Russia. Participants were patients attending a
general practitioner or specialist who prescribed
insulin analogs in their routine practice;
participants were enrolled in the study between
January 2009 and June 2010. Further details on
inclusion and exclusion criteria, and study design
have previously been reported [24].
Insulin analogs were used in the study in
accordance with the label approved by the
regulatory authority (all manufactured by Novo
Nordisk A/S, Bagsvaerd, Denmark), and all local
requirements for Health Authorities or Ethics
Committee approvals were obtained, if
applicable. In every country, participants signed
informed consent forms andwere free to withdraw
from the study at any time. The study was
conducted in accordance with the Declaration of
Helsinki of 1964, as revised in 2008 [25] and
guidelines for good pharmacoepidemiology
practice [26].
Assessments and Outcome Measures
Trial visits were defined as baseline, interim
[around 12 weeks from baseline (results not
reported here)], and final visit (around
24 weeks from baseline). The amount of
starting insulin and the amount of insulin
administered at subsequent visits were recorded.
The primary objective was to evaluate the
safety profile of insulin analogs by measuring the
incidence of serious adverse drug reactions
(SADRs), including major hypoglycemia events.
Other safety assessments included the change in
the number of hypoglycemia events (overall,
Diabetes Ther (2013) 4:347–361 349
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major, nocturnal) between baseline and 24 weeks.
These were based on patient recall of events
within the 4 weeks preceding each study visit.
A hypoglycemia event was defined as an event
with symptoms of hypoglycemia that resolved
with oral carbohydrate intake, glucagon or
intravenous glucose, or any symptomatic or
asymptomatic event where plasma glucose was
\3.1 mmol/l or 56 mg/dl. Major hypoglycemia
events were defined as events with severe central
nervous system symptoms consistent with
hypoglycemia in which the patient was unable
to self-treat and had one of the following
characteristics: plasma glucose \3.1 mmol/l, or
reversal of symptoms after either food intake,
glucagon or intravenous glucose administration.
Nocturnal hypoglycemia events were defined as
individualized symptomatic events consistent
with hypoglycemia between bedtime after the
evening insulin injection and before getting up in
the morning; if applicable, events were those that
occurred before morning determination of FPG
and the morning insulin injection.
Effectiveness measurements were secondary
endpoints, and included the change in HbA1c,
FPG levels before breakfast, PPG levels after
breakfast, body weight, and health-related
quality of life (HRQoL) between baseline and
24 weeks.
HRQoL was assessed at baseline and after
24 weeks by self-reporting using the EQ-5D
questionnaire [27], which evaluates five domains
of patient health/lifestyle (mobility, self-care,
usual activities, pain/discomfort, and anxiety/
depression). Patient responses were evaluated on
a visual analog scale (VAS) of 0 (worst imaginable
health) to 100 (best imaginable health).
Statistical Analysis
This publication reports the results for patients
who were administered biphasic insulin aspart
30 (±OGLDs) in the A1chieve study. Analysis of
each of the safety and effectiveness outcome
measures was performed by age-group (B40,
[40–65, and [65 years) and pre-study insulin
experience (insulin-experienced and insulin-
naı¨ve) for those receiving biphasic insulin
aspart 30 (±OGLDs). The age-groups were
arbitrarily selected. All analyses were
performed on the full analysis set, which was
defined as all patients with a baseline visit and
who used study insulin at least once. For
hypoglycemia, the percentage of participants
reporting at least one event was analyzed using
McNemar’s test. The number of SADRs deemed
to be related to study insulin was also reported.
Change from baseline data in effectiveness
measures were analyzed using paired t test. All
data were analyzed by Novo Nordisk A/S using
SAS Version 9.1.3 (SAS Institute Inc., Cary,
NC, USA). The statistical significance level
employed was a = 0.05 (two tailed). Missing
data were not imputed. The sample size was
based on the number of people (20,000)
exposed for 6 months required to confirm at
95% confidence a frequency of any one adverse




Of the total A1chieve study population, 40,122
people with type 2 diabetes received treatment
with biphasic insulin aspart 30 (±OGLDs). This
included 4,347 people aged B40 years, 29,036
people aged [40–65 years, and 6,739 people
aged [65 years (Table 1). Due to the non-
interventional nature of the study, some
baseline data were missing and some patients
were missing to follow-up. Most study
350 Diabetes Ther (2013) 4:347–361
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participants (67%) were insulin-naı¨ve before the
study. The [65 years age-group had the longest
diabetes duration (Table 1).
Exposure
The difference between the starting insulin dose
and the insulin dose at 24 weeks in any age-
group was small. In the B40 years age-group, the
starting mean (SD) total insulin dose was 0.46
(0.21) U/kg (n = 4,161) and at 24 weeks was 0.50
(0.25) U/kg (n = 3,203). In the[40–65 years age-
group, the starting total insulin dose was 0.46
(0.20) U/kg (n = 27,738) and at 24 weeks was
0.51 (0.24) U/kg (n = 22,004). In the [65 years
age-group, starting total insulin dose was 0.47
(0.21) U/kg (n = 6,361) and at 24 weeks was 0.52
(0.23) U/kg (n = 4,964).
This pattern was repeated in the insulin-
naı¨ve and insulin-experienced subgroups:
insulin-naı¨ve patients, 0.42 U/kg at baseline
(B40 years: n = 3,123;[40–65 years: n = 19,188;
[65 years: n = 3,613) and 0.46–0.47 U/kg after
24 weeks (B40 years: n = 2,447; [40–65 years:
n = 15,148; [65 years: n = 2,778) in the 3 age-
groups; insulin-experienced patients,
0.54–0.59 U/kg at baseline (B40 years:
n = 1,038; [40–65 years: n = 8,550; [65 years:
n = 2,748) and 0.59–0.64 U/kg at 24 weeks
(B40 years: n = 756; [40–65 years: n = 6,856;
[65 years: n = 2,186) in the 3 age-groups.
The number of concomitant OGLDs used
remained stable during the course of the
24 weeks of biphasic insulin aspart 30 therapy
(Table 2); although the [65 years age-group
tended to be receiving less OGLDs at 24 weeks
than the B40 and [40–65 years age-groups,
there was no major difference in OGLD use
between the age-groups (Table 2). Metformin
and/or sulfonylureas were the predominant
OGLDs in all age-groups at study initiation
and after 24 weeks of treatment with biphasic
Table 1 Baseline patient and disease characteristics by age-group
£40 years >40–65 years >65 years
Entire cohort, n 4,347 29,036 6,739
Insulin status
Insulin-experienced, n (%) 1,109 (25.5) 8,998 (31.0) 2,943 (43.7)
Insulin-naı¨ve, n (%) 3,238 (74.5) 20,038 (69.0) 3,796 (56.3)
Mean (SD) age (years) 33.3 (8.5) 53.1 (6.5) 71.3 (5.0)
Male, n (%)a 2,663 (61.3) 16,463 (56.8) 3,333 (49.5)
Mean (SD) weight (kg)b 71.0 (14.0) 72.0 (13.8) 69.1 (13.8)
Mean (SD) BMI (kg/m2)c 25.8 (4.4) 26.8 (4.6) 26.3 (4.8)
Mean (SD) diabetes duration (years)d 3.9 (3.7) 7.3 (5.3) 11.4 (8.0)
Due to the non-interventional nature of this study, not all baseline data were recorded and some patients were lost to
follow-up
BMI body mass index
a n = 4,342, n = 29,008 and n = 6,739 for the B40 years,[40–65 years and[65 years age-groups, respectively
b n = 4,161, n = 27,744, and n = 6,361 for the B40 years,[40–65 years and[65 years age-groups, respectively
c n = 3,916, n = 25,885, and n = 5,892 for the B40 years,[40–65 years and[65 years age-groups, respectively
d n = 4,109, n = 28,815 and n = 6,673 for the B40 years,[40–65 years and[65 years age-groups, respectively
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insulin aspart 30; [70% of patients in all age-




After 24 weeks, the proportion of participants
experiencing hypoglycemia events in the
entire cohort decreased significantly from
baseline in all age-groups (all p\0.01;
Table 3). This pattern was also seen among
insulin-experienced participants (all p\0.001;
Table 3). As with the insulin-experienced
group, there was a significant reduction in
the proportion of insulin-naı¨ve participants
experiencing hypoglycemia in the B40 years
age-group (p\0.05); however, there was
no statistically significant change in the
[40–65 years age-group and a significant
increase in the [65 years age-group (p\0.001;
Table 3). There did not appear to be a trend
between the length of time in years from
diagnosis of diabetes and total hypoglycemia
events (results not shown). Neither did there
seem to be an association between sulfonylurea
use and the total number of hypoglycemia
events (Table 3).
Major Hypoglycemia Events
The proportions of participants experiencing
major hypoglycemia in the entire cohort and in
insulin-experienced patients decreased
significantly from baseline in all age-groups
following 24 weeks’ therapy with biphasic
insulin aspart 30 (all p\0.001; Table 3). In
insulin-naı¨ve patients, there were significant
reductions from baseline in the proportion of
participants experiencing major hypoglycemia
in the [40–65 years and [65 years age-groups
(both p\0.001; Table 3), but no significant
difference from baseline in the B40 years age-
group.
Nocturnal Hypoglycemia Events
The proportions of participants experiencing
nocturnal hypoglycemia in the entire cohort
and in insulin-experienced patients decreased
significantly from baseline in all age-groups
following 24 weeks’ therapy with biphasic
insulin aspart 30 (all p\0.001; Table 3). The
proportion of insulin-naı¨ve patients
experiencing nocturnal hypoglycemia was
significantly reduced in the B40 and
[40–65 years age-groups at 24 weeks (both
p\0.001), with no significant change reported
in the[65 years age-group (Table 3).
Table 2 Number of OGLDs taken at baseline and following 24 weeks of therapy with biphasic insulin aspart 30
Number of OGLDs £40 years >40–65 years >65 years
Baseline 24 weeks Baseline 24 weeks Baseline 24 weeks
All, n 4,347 3,620 29,036 25,134 6,739 5,688
No OGLDs, n (% of cohort) 1,629 (37.5) 1,166 (32.2) 8,421 (29.0) 6,489 (25.8) 2,815 (41.8) 2,256 (39.7)
One OGLD, n (% of cohort) 1,654 (38.0) 1,388 (38.3) 13,000 (44.8) 11,240 (44.7) 2,677 (39.7) 2,420 (42.5)
CTwo OGLDs, n (% of cohort) 1,064 (24.5) 1,066 (29.4) 7,615 (26.2) 7,405 (29.5) 1,247 (18.5) 1,012 (17.8)
Due to the non-interventional nature of this study, not all baseline data were recorded and some patients were lost to
follow-up
OGLDs oral glucose-lowering drugs
352 Diabetes Ther (2013) 4:347–361
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Table 3 Safety outcomes before and after 24 weeks of treatment with biphasic insulin aspart 30 by age-group
Measurement £40 years >40–65 years >65 years
Baseline 24 weeks Baseline 24 weeks Baseline 24 weeks
Overall hypoglycemia, % patients with at least one event (event/person-year)
Entire cohort 7.3 (2.27) 4.4*** (1.06) 7.3 (2.26) 5.4*** (1.39) 9.2 (3.17) 7.9** (2.11)
n 4,347 3,620 29,036 25,134 6,739 5,688
Insulin-experienced 16.2 (6.54) 8.9*** (2.19) 14.9 (5.15) 8.3*** (2.22) 16.2 (5.99) 10.3*** (2.90)
n 1,109 868 8,998 7,712 2,943 2,502
Insulin-naı¨ve 4.2 (0.80) 3.0* (0.71) 3.9 (0.96) 4.1 (1.02) 3.8 (0.99) 6.1*** (1.49)
n 3,238 2,752 20,038 17,422 3,796 3,186
Sulfonylurea 5.5 (1.20) 1.0*** (0.16) 5.3 (1.43) 2.2*** (0.46) 6.5 (2.00) 4.8 (0.92)
n 1,967 1,041 16,095 6,555 2,948 875
Non-sulfonylurea 8.8 (3.15) 5.8 (1.43) 9.9 (3.29) 6.6*** (1.72) 11.3 (4.08) 8.5* (2.33)
n 2,380 2,579 12,941 18,579 3,791 4,813
Major hypoglycemia, % patients with at least one event (event/person-year)
Entire cohort 1.2 (0.25) 0.0*** (0.00) 1.1 (0.20) 0.0*** (0.01) 1.6 (0.35) 0.1*** (0.03)
n 4,347 3,620 29,036 25,134 6,739 5,688
Insulin-experienced 4.2 (0.89) 0*** (0) 2.4 (0.45) 0.1*** (0.01) 2.7 (0.60) 0.2*** (0.06)
n 1,109 868 8,998 7,712 2,943 2,502
Insulin-naı¨ve 0.2 (0.03) 0.0 (0.01) 0.5 (0.08) 0.0*** (0.00) 0.8 (0.15) 0*** (0)
n 3,238 2,752 20,038 17,422 3,796 3,186
Nocturnal hypoglycemia, % patients with at least one event (event/person-year)
Entire cohort 3.2 (0.63) 1.2*** (0.20) 3.1 (0.65) 1.5*** (0.29) 3.6 (0.93) 2.6*** (0.52)
n 4,347 3,620 29,036 25,134 6,739 5,688
Insulin-experienced 8.0 (1.78) 3.3*** (0.51) 6.6 (1.51) 2.5*** (0.49) 6.6 (1.72) 3.8*** (0.76)
n 1,109 868 8,998 7,712 2,943 2,502
Insulin-naı¨ve 1.5 (0.24) 0.5*** (0.10) 1.5 (0.27) 1.1*** (0.20) 1.3 (0.32) 1.6 (0.33)
n 3,238 2,752 20,038 17,422 3,796 3,186
Body weight (SD), kg
Entire cohort 70.8 (13.5) 71.1*** (13.0) 72.3 (13.6) 72.5*** (13.0) 69.5 (13.4) 70.1*** (12.9)
n 3,182 21,757 4,873
Insulin-experienced 72.9 (15.5) 73.2* (15.1) 75.8 (15.0) 75.9* (14.5) 72.0 (14.3) 72.3*** (14.0)
n 747 6,751 2,136
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SADRs
Of the 40,122 people receiving biphasic insulin
aspart 30 (±OGLDs), there were 16 reports of
SADRs: 5 in the B40 years age-group, including 3
hypoglycemia episodes, 1 report of diabetic
ketoacidosis, and 1 episode of hypoglycemia
unawareness; 5 in the [40–65 years age-group,
including 3 hypoglycemia episodes, 1 report of
hyperglycemia, and 1 episode of hypoglycemia
unawareness; and 6 in the [65 years age-group,
including 5 hypoglycemia episodes and 1 episode
of hypoglycemia unawareness. Ten of these were
probably related to biphasic insulin aspart 30
(±OGLDs) treatment (with good reasons and
sufficient documentation to assume a causal
relationship) and 6 were possibly related (a causal
relationship was conceivable and could not be
dismissed).
Body Weight
There was a modest, but statistically significant
(p\0.001),weightgain (0.2–0.7 kg)after24 weeks
in all age-groups (Table 3). Weight gain with
biphasic insulin aspart 30 treatment appeared to
besimilar inboth insulin-experiencedandinsulin-
naı¨ve patients (Table 3).
Effectiveness Measures
Glycemic Measures
Mean baseline HbA1c levels were high in all age-
groups (ranging from 9.4% to 9.6%), and after
24 weeks of treatment with biphasic insulin
aspart 30, all age-groups showed statistically
significant improvements (p\0.001; Table 4).
Likewise, HbA1c levels were statistically
significantly reduced in all age-groups after
24 weeks in insulin-experienced and insulin-
naı¨ve patients (p\0.001; Table 4). In all age-
groups, improvements in HbA1c values
appeared to be greater in insulin-naı¨ve
patients than in insulin-experienced patients
(Table 4). The length of time since diagnosis of
diabetes in years did not appear to affect the
magnitude of reduction in HbA1c levels after
24 weeks of biphasic insulin aspart 30 treatment
(results not shown).
Mean baseline FPG was high in all age-
groups (ranging from 10.5 to 11.1 mmol/l),
and there were significant improvements in all
age-groups after 24 weeks’ treatment with
biphasic insulin aspart 30 (Table 4).
Improvements in FPG appeared to be slightly
greater in the insulin-naı¨ve group than the
insulin-experienced group after 24 weeks in all
age-groups (Table 4). Likewise, baseline PPG was
high in all age-groups, and after 24 weeks’
treatment with biphasic insulin aspart 30,
statistically significantly improvements were
observed in all age-groups (Table 4).
Improvements after 24 weeks appeared to be
greater in the insulin-naı¨ve group in all age-
groups (Table 4). Improvements in FPG and PPG
levels at 24 weeks appeared to be greatest in the
Table 3 continued
Measurement £40 years >40–65 years >65 years
Baseline 24 weeks Baseline 24 weeks Baseline 24 weeks
Insulin-naı¨ve 70.2 (12.8) 70.4** (12.3) 70.7 (12.6) 70.9*** (12.0) 67.5 (12.3) 68.5*** (11.7)
n 2,435 15,006 2,737
Due to the non-interventional nature of this study, not all baseline data were recorded and some patients were lost to follow-up
*** p\0.001 vs. baseline
** p\0.01 vs. baseline
* p\0.05 vs. baseline
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B40 years age-group and least in [65 years age-
group.
HRQoL
There was statistically significant (p\0.001)
improvement in VAS scores after 24 weeks in
all age-groups (Table 4). Statistically significant
increases in VAS scores were observed for both
insulin-experienced and insulin-naı¨ve patients
in all age-groups (p\0.001; Table 4).
DISCUSSION
This sub-analysis of age-specific data from the
A1chieve study showed that starting, or
switching to, insulin therapy with biphasic
insulin aspart 30 (±OGLDs) under routine
clinical practice led to significant
improvements in blood glucose levels (as
measured by HbA1c, FPG and PPG) across 3
age-groups. These results are consistent with
previous studies that showed in people with
type 2 diabetes that starting insulin therapy
with once- or twice-daily biphasic insulin aspart
30 led to effective glycemic control [18, 19].
Another study also showed that biphasic insulin
aspart 30 may lead to improved PPG control
compared with other insulin therapies [20].
Importantly, the significant improvement in
glycemic control was achieved with a
significant reduction in the proportion of
participants in the entire cohort reporting
major hypoglycemia during the 24 weeks of
treatment with biphasic insulin aspart 30
(±OGLDs) relative to baseline. The results
appeared to be generally consistent across the
3 age-groups assessed and between insulin-
naı¨ve and insulin-experienced patients. Some
variation in the specific pattern of results was
observed and these will be discussed.
The reduction in the incidence of
hypoglycemia observed for the entire cohort
in all age-groups may potentially be explained
by the reduced sulfonylurea use after 24 weeks,
but may also be due to optimization of the
biphasic insulin aspart 30 dosage during the
24 weeks of the study. Others have reported a
lower proportion of people experiencing
hypoglycemia in patients receiving biphasic
insulin aspart 30 who have optimized their
insulin dosage [28]. Furthermore, the
proportion of participants reporting
hypoglycemia was significantly reduced in all
age-groups switching from other insulin
regimens to biphasic insulin aspart 30
treatment, as would be expected from the
significant reductions in the whole A1chieve
study population [24]. This result may also have
been driven by the high baseline values in all
age-groups of insulin-experienced participants.
However, while the proportion was also
significantly reduced in insulin-naı¨ve patients
aged B40 years, it was significantly increased in
the [65 years age-group. Elderly individuals
with diabetes are at higher risk of
hypoglycemia than younger people due to risk
factors such as co-morbidities, polypharmacy,
and cognitive impairment [29]—this may
explain the age differences in hypoglycemia
rates. Reported major hypoglycemia episodes
were rare during treatment with biphasic
insulin aspart 30, as seen in other non-
interventional studies [30], with statistically
significant improvements from baseline in all
age-groups. Furthermore, there was a low
incidence of SADRs in all three age-groups,
with no suggestion that these were more likely
in one group over another. While it is not
surprising that patients already receiving
insulin therapy at baseline had what appeared
to be higher rates of overall hypoglycemia,
major hypoglycemia and nocturnal
hypoglycemia than those who were insulin-
naı¨ve pre-study, it is unclear why the
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proportion of patients reporting nocturnal
hypoglycemia at baseline appeared to be much
higher among insulin-experienced patients in
the B40 years age-group.
Changes to body weight with biphasic
insulin aspart 30 therapy were modest
(generally \1 kg); weight gain was greatest in
the [65 years age-group, but the differences
between age-groups were not large and may not
have any clinical relevance. As expected,
insulin-experienced patients appeared to weigh
more at baseline than insulin-naı¨ve participants
in all age-groups, but there was no clear
difference in weight gain between the 2 groups
after 24 weeks in any age-group. Other studies
have reported weight gain with use of biphasic
insulin aspart 30 [12, 19, 31]; for example, in an
open-label, controlled trial of patients with type
2 diabetes and suboptimal HbA1c, 1-year
treatment with biphasic insulin aspart 30 plus
metformin and sulfonylurea was associated
with a mean weight gain of 4.7 kg [32].
Reductions in FPG and PPG appeared to be
greater in insulin-naı¨ve patients than in insulin-
experienced patients, possibly because baseline
levels were higher among insulin-naı¨ve patients.
This baseline finding is consistent with baseline
results in the IMPROVE and Physicians’ Routine
Evaluation of Safety and Efficacy of NovoMix 30
Therapy non-interventional studies of people
with type 2 diabetes starting or switching to
biphasic insulin aspart as part of routine clinical
care [15, 16]. As would be expected following
these significant reductions in FPG and PPG
after 24 weeks, clinically meaningful
improvements in HbA1c values were seen in
both the insulin-naı¨ve and insulin-experienced
participants in all age-groups, and the
improvements seemed to be slightly larger for
the insulin-naı¨ve participants. However, this
was not caused by higher baseline HbA1c values
among insulin-naı¨ve patients, as both patient
groups appeared to have similar baseline HbA1c
values. That clinically meaningful
improvements in HbA1c values were seen in the
[65 years age-group is encouraging given the
additional challenges elderly patients face in
managing their diabetes, such as cognitive
impairment, co-morbidities and polypharmacy,
among other issues.
Although participation in the study alone
could improve perceived HRQoL regardless of
treatment, it is encouraging that starting or
switching to biphasic insulin aspart 30
significantly improved HRQoL in all age-
groups, as reported previously for the total
A1chieve population [33].
There are limitations to the current study
that are inherent in the study design of non-
interventional studies. These include the lack of
randomization and the absence of a control arm,
and assessment of some parameters (e.g.,
hypoglycemia events) being based on
participant recall and self-reported
information. In addition, this study did not
control for concomitant medication and dietary
intake. However, non-interventional studies
have the advantages of enabling a larger body
of data to be analyzed and a greater variety of
important disease and therapy-related questions
to be explored than can be assessed in an RCT.
In summary, this sub-analysis of data from
the A1chieve study suggests that in people with
type 2 diabetes with poor glycemic control,
starting or switching to biphasic insulin aspart
30 (±OGLDs) provides valuable improvements
in glycemic control. Importantly, the
effectiveness and tolerability of biphasic
insulin aspart 30 are consistent across different
age-groups. This is particularly reassuring in the
elderly population who may face more
challenges to achieving glycemic control
compared with younger patients. Furthermore,
hypoglycemia episodes reported in insulin-
358 Diabetes Ther (2013) 4:347–361
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naı¨ve patients aged[65 years suggest that there
should be a greater focus on education when
elderly people are initiating insulin therapy.
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